BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31536651)

  • 1. Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network.
    Frezza AM; Assi T; Lo Vullo S; Ben-Ami E; Dufresne A; Yonemori K; Noguchi E; Siontis B; Ferraro R; Teterycz P; Duffaud F; Ravi V; Vincenzi B; Gelderblom H; Pantaleo MA; Baldi GG; Desar I; Fedenko A; Maki RG; Jones RL; Benjamin RS; Blay JY; Kawai A; Gounder M; Gronchi A; Le Cesne A; Mir O; Czarnecka AM; Schuetze S; Wagner AJ; Adam J; Barisella M; Sbaraglia M; Hornick JL; Meurgey A; Mariani L; Casali PG; Thornton K; Stacchiotti S
    Cancer; 2020 Jan; 126(1):98-104. PubMed ID: 31536651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series.
    Frezza AM; Jones RL; Lo Vullo S; Asano N; Lucibello F; Ben-Ami E; Ratan R; Teterycz P; Boye K; Brahmi M; Palmerini E; Fedenko A; Vincenzi B; Brunello A; Desar IME; Benjamin RS; Blay JY; Broto JM; Casali PG; Gelderblom H; Grignani G; Gronchi A; Hall KS; Mir O; Rutkowski P; Wagner AJ; Anurova O; Collini P; Dei Tos AP; Flucke U; Hornick JL; Lobmaier I; Philippe T; Picci P; Ranchere D; Renne SL; Sbaraglia M; Thway K; Wagrodzki M; Wang WL; Yoshida A; Mariani L; Kawai A; Stacchiotti S
    JAMA Oncol; 2018 Sep; 4(9):e180219. PubMed ID: 29800950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma.
    Gounder MM; Merriam P; Ratan R; Patel SR; Chugh R; Villalobos VM; Thornton M; Van Tine BA; Abdelhamid AH; Whalen J; Yang J; Rajarethinam A; Duh MS; Bobbili PJ; Huynh L; Totev TI; Lax AK; Agarwal S; Demetri GD
    Cancer; 2021 Apr; 127(8):1311-1317. PubMed ID: 33296083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas).
    Sanfilippo R; Jones RL; Blay JY; Le Cesne A; Provenzano S; Antoniou G; Mir O; Fucà G; Fumagalli E; Bertulli R; Stacchiotti S; Brahmi M; Grosso F; Dufresne A; Hindi N; Sbaraglia M; Gronchi A; Collini P; Dei Tos AP; Casali PG
    Clin Cancer Res; 2019 Sep; 25(17):5295-5300. PubMed ID: 31217199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial.
    Schmoll HJ; Lindner LH; Reichardt P; Heißner K; Kopp HG; Kessler T; Mayer-Steinacker R; Rüssel J; Egerer G; Crysandt M; Kasper B; Niederwieser D; Kunitz A; Eigendorff E; Petersen I; Steighardt J; Cygon F; Meinert F; Stein A
    JAMA Oncol; 2021 Feb; 7(2):255-262. PubMed ID: 33355646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma.
    Somaiah N; Van Tine BA; Wahlquist AE; Milhem MM; Hill EG; Garrett-Mayer E; Armeson KE; Schuetze SM; Meyer CF; Reuben DY; Elias AD; Read WL; Chawla SP; Kraft AS
    Cancer; 2021 Mar; 127(6):894-904. PubMed ID: 33231866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.
    Stacchiotti S; Mir O; Le Cesne A; Vincenzi B; Fedenko A; Maki RG; Somaiah N; Patel S; Brahmi M; Blay JY; Boye K; Sundby Hall K; Gelderblom H; Hindi N; Martin-Broto J; Kosela H; Rutkowski P; Italiano A; Duffaud F; Kobayashi E; Casali PG; Provenzano S; Kawai A
    Oncologist; 2018 Jan; 23(1):62-70. PubMed ID: 28754721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas.
    Munhoz RR; D'Angelo SP; Gounder MM; Keohan ML; Chi P; Carvajal RD; Singer S; Crago AM; Landa J; Healey JH; Qin LX; Hameed M; Ezeoke MO; Singh AS; Agulnik M; Chmielowski B; Luke JJ; Van Tine BA; Schwartz GK; Tap WD; Dickson MA
    Oncologist; 2015 Nov; 20(11):1245-6. PubMed ID: 26449382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature.
    Frezza AM; Ravi V; Lo Vullo S; Vincenzi B; Tolomeo F; Chen TW; Teterycz P; Baldi GG; Italiano A; Penel N; Brunello A; Duffaud F; Hindi N; Iwata S; Smrke A; Fedenko A; Gelderblom H; Van Der Graaf W; Vozy A; Connolly E; Grassi M; Benjamin RS; Broto JM; Grignani G; Jones RL; Kawai A; Tysarowski A; Mariani L; Casali PG; Stacchiotti S
    Cancer Med; 2021 Apr; 10(8):2645-2659. PubMed ID: 33713582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma.
    Kim JH; Park HS; Heo SJ; Kim SK; Han JW; Shin KH; Kim SH; Hur H; Kim KS; Choi YD; Kim S; Lee YH; Suh JS; Ahn JB; Chung HC; Noh SH; Rha SY; Kim HS
    Oncology; 2019; 96(2):59-69. PubMed ID: 30336470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers.
    Van Tine BA; Trent JC
    Curr Med Res Opin; 2019 Apr; 35(4):623-629. PubMed ID: 30652922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study).
    Pautier P; Penel N; Ray-Coquard I; Italiano A; Bompas E; Delcambre C; Bay JO; Bertucci F; Delaye J; Chevreau C; Cupissol D; Bozec L; Eymard JC; Saada E; Isambert N; Guillemet C; Rios M; Piperno-Neumann S; Chenuc G; Duffaud F
    Eur J Cancer; 2020 Jan; 125():31-37. PubMed ID: 31835236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients.
    Schuler MK; Gerdes S; West A; Richter S; Busemann C; Hentschel L; Lenz F; Kopp HG; Ehninger G; Reichardt P; Pink D
    BMC Cancer; 2016 Aug; 16():619. PubMed ID: 27507014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.
    Kollár A; Jones RL; Stacchiotti S; Gelderblom H; Guida M; Grignani G; Steeghs N; Safwat A; Katz D; Duffaud F; Sleijfer S; van der Graaf WT; Touati N; Litière S; Marreaud S; Gronchi A; Kasper B
    Acta Oncol; 2017 Jan; 56(1):88-92. PubMed ID: 27838944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis.
    Baldi GG; Brahmi M; Lo Vullo S; Cojocaru E; Mir O; Casanova M; Vincenzi B; De Pas TM; Grignani G; Pantaleo MA; Blay JY; Jones RL; Le Cesne A; Frezza AM; Gronchi A; Collini P; Dei Tos AP; Morosi C; Mariani L; Casali PG; Stacchiotti S
    Oncologist; 2020 Nov; 25(11):e1777-e1784. PubMed ID: 32584482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial.
    Stacchiotti S; Ferrari S; Redondo A; Hindi N; Palmerini E; Vaz Salgado MA; Frezza AM; Casali PG; Gutierrez A; Lopez-Pousa A; Grignani G; Italiano A; LeCesne A; Dumont S; Blay JY; Penel N; Bernabeu D; de Alava E; Karanian M; Morosi C; Brich S; Dagrada GP; Vallacchi V; Castelli C; Brenca M; Racanelli D; Maestro R; Collini P; Cruz J; Martin-Broto J
    Lancet Oncol; 2019 Sep; 20(9):1252-1262. PubMed ID: 31331701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 dual-color in situ hybridization (DISH) aids the diagnosis of intimal sarcomas.
    Jimbo N; Komatsu M; Itoh T; Hirose T
    Cardiovasc Pathol; 2019; 43():107142. PubMed ID: 31442826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
    Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
    Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma.
    Subbiah V; Meyer C; Zinner R; Meric-Bernstam F; Zahurak ML; O'Connor A; Roszik J; Shaw K; Ludwig JA; Kurzrock R; Azad NA
    Clin Cancer Res; 2017 Aug; 23(15):4027-4034. PubMed ID: 28377484
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical Outcome of Systemic Treatment for Advanced Soft Tissue Sarcoma: Real-Life Perspective in Japan.
    Nakamura T; Asanuma K; Hagi T; Sudo A
    Drug Des Devel Ther; 2020; 14():4215-4220. PubMed ID: 33116409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.